← Russell 3000 cross-section

ALGN ALIGN TECHNOLOGY INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$11.4bn
Revenue TTM
$4.1bn
Net income TTM
$414m
Free cash flow
$634m
Composite score
67.8
Sector rank
#659

Valuation

P / E
27.5
EV / EBITDA
12.8
EV / sales
2.5
FCF yield
5.57%
Earnings yield vs 10-yr
-1.10pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
10.0%
EBITDA margin
19.4%
ROE
9.8%
ROIC
17.5%
Revenue growth
4.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For the three and six months ended June 30, 2026, total net revenues increased by $44 million and $105 million compared to the same period in 2025, primarily due to an increase in Clear Aligner volume and increased ASPs. Clear Aligner For the three months ended June 30, 2026, Clear Aligner net revenues increased by $66 million compared to the same period in 2025, primarily due to an increase in volume, which increased net revenues by $53 million and an increase of $13 million from favorable foreign exchange rates and price increases. …ALIGN TECHNOLOGY INC, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →